What the company does
IL Dong Pharmaceutical makes prescription medicines, active-vitamin supplements (sold under the Aronamin brand), antibiotics, health supplements, and specialty nutritional foods for patients and consumers in South Korea.
Its products reach end users through the domestic healthcare and retail supply chain. Listed on KOSPI, South Korea's main stock exchange, the company's product range is anchored by its active-vitamin Aronamin line and the antibiotic Flumarin, which together represent its core manufactured goods.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$410.8M
▼ −7.8% YoY
Operating profit · FY2025
US$14.1M
▲ +48.5% YoY
Net income · FY2025
US$17.2M
Turned profitable
Revenue
- FY2023US$435.3M
- FY2024US$445.6M
- FY2025US$410.8M
Operating profit
- FY2023−US$39.1M
- FY2024US$9.5M
- FY2025US$14.1M
Net income
- FY2023−US$58.7M
- FY2024−US$9M
- FY2025US$17.2M
Key ratios (FY2025)
ROE
9.9%
Debt/Eq
139.3%
Op. margin
3.4%
Net margin
4.2%
Rev. YoY
▼ −7.8%
Price charts coming soon
Interactive price history isn't here yet. Would you use it?